Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

Traws Pharma, Inc.

TRAW · Nasdaq · CIK 0001130598 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

0 Form 4 transaction lines observed in the same window
0 sales · 0 option, withholding, award, gift or other lines

Last qualifying purchase2026-04-16 · ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC · $998.2K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesNone
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

Insider activity timeline

No Form 4 transaction event is present in the current 180-day window.

SIGNAL HISTORY

48.9 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 47.8
  2. 48.9
  3. 48.9

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

1Purchases
0Sales
9Other Form 4 lines
10SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-15.1%
3M
-33.8%
6M
-69.6%
12M
-81.9%

Volatility & liquidity

Volatility
159.4%
Beta
—
Avg daily value
USD 263,134

Valuation

Market cap
USD 6.9M
P/E
0.8×

Fundamentals

Profit margin
328.7%
ROE
—
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, P/E, Profit margin · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-12 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
690,685
Previous report
612,216
Avg daily volume
2,784,333
Days to cover
≤ 1.0

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-04-16ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCPurchase (P)Common Stock597,729USD 1.67USD 998,207SEC filing ↗
2022-01-28OLER ABRAHAM N.Purchase (P)Common Stock1,500USD 1.67USD 2,505SEC filing ↗
2022-01-21OLER ABRAHAM N.Purchase (P)Common Stock1,500USD 2.02USD 3,030SEC filing ↗
2022-01-14OLER ABRAHAM N.Purchase (P)Common Stock1,500USD 2.20USD 3,300SEC filing ↗
2022-01-07OLER ABRAHAM N.Purchase (P)Common Stock1,500USD 2.39USD 3,585SEC filing ↗
2021-11-19OLER ABRAHAM N.Purchase (P)Common stock1,000USD 3.16USD 3,160SEC filing ↗
2021-09-28OLER ABRAHAM N.Purchase (P)Common Stock2,381USD 4.20USD 10,000SEC filing ↗
2021-09-28Gelder Mark S. MDPurchase (P)Common Stock2,381USD 4.20USD 10,000SEC filing ↗
2021-09-28MARINO JAMES JPurchase (P)Common Stock5,952USD 4.20USD 24,998SEC filing ↗
2021-09-28Fruchtman Steven MPurchase (P)Common Stock2,381USD 4.20USD 10,000SEC filing ↗
2021-02-16Shoemaker Mary TeresaPurchase (P)Common Stock13,000USD 1.00USD 13,000SEC filing ↗
2021-02-16OLER ABRAHAM N.Purchase (P)Common Stock12,000USD 1.00USD 12,000SEC filing ↗
2021-02-16MARINO JAMES JPurchase (P)Common Stock25,000USD 1.00USD 25,000SEC filing ↗
2021-02-16Guerin Mark PatrickPurchase (P)Common Stock15,000USD 1.00USD 15,000SEC filing ↗
2021-02-16Fruchtman Steven MPurchase (P)Common Stock20,000USD 1.00USD 20,000SEC filing ↗

Form 4 evidence

10 transaction lines in the latest 365-day window; 81 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-04-16ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCPurchase (P)Common Stock597,729USD 1.67USD 998,207SEC filing ↗
2025-12-12Shoemaker Mary TeresaAward / grant (A)Common Stock6,157USD 0.00USD 0SEC filing ↗
2025-12-12Savchuk NikolayAward / grant (A)Common Stock16,419USD 0.00USD 0SEC filing ↗
Show recent Form 4 evidence (10 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-04-16ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCPurchase (P)Common Stock597,729USD 1.67USD 998,207SEC filing ↗
2025-12-12Shoemaker Mary TeresaAward / grant (A)Common Stock6,157USD 0.00USD 0SEC filing ↗
2025-12-12Savchuk NikolayAward / grant (A)Common Stock16,419USD 0.00USD 0SEC filing ↗
2025-12-12STOVER JACK EAward / grant (A)Common Stock6,157USD 0.00USD 0SEC filing ↗
2025-12-12Redfield RobertAward / grant (A)Common Stock16,419USD 0.00USD 0SEC filing ↗
2025-12-12Pauza Charles DavidAward / grant (A)Common Stock18,471USD 0.00USD 0SEC filing ↗
2025-12-12Leaman John HaroldAward / grant (A)Common Stock4,058USD 0.00USD 0SEC filing ↗
2025-12-12Dukes Iain D.Award / grant (A)Common Stock36,943USD 0.00USD 0SEC filing ↗
2025-12-12Clarke TraffordAward / grant (A)Common Stock6,157USD 0.00USD 0SEC filing ↗
2025-12-12CAUTREELS WERNERAward / grant (A)Common Stock4,874USD 0.00USD 0SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerTRAW
CIK0001130598
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history81 transaction lines from 2020-05-19 to 2026-04-16
26 P purchase lines · 3 S sale lines · 52 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.